Lilly(US:LLY) GLP1减重宝典·2026-02-27 08:15Core Viewpoint - The article discusses the significant results of Eli Lilly's oral GLP-1 receptor agonist Orforglipron in a head-to-head trial against oral semaglutide, highlighting its superior efficacy in both glycemic control and weight loss for type 2 diabetes patients [5][6]. Group 1: Clinical Trial Results - Eli Lilly's Orforglipron demonstrated a more pronounced dose-response relationship in the ACHIEVE-3 trial, showing a greater reduction in HbA1c levels compared to oral semaglutide at a dosage of 14mg, along with a more significant weight loss [5]. - The trial lasted for 52 weeks, providing robust evidence of Orforglipron's efficacy in a direct comparison rather than relying on indirect comparisons from different studies [5]. Group 2: Market Positioning - In the diabetes indication, the head-to-head victory of Orforglipron is crucial as it establishes the oral small molecule not only as a convenient option but also as a potentially more effective treatment [6]. - The oral formulation is expected to have advantages in production and supply chain scalability, making it more accessible and cost-effective in real-world applications [6]. Group 3: Weight Loss Indication - In the obesity indication, the market is more focused on the extent and stability of weight loss rather than just the ability to lose weight [6]. - Orforglipron's results in the ATTAIN-1 trial showed a double-digit weight loss in the high-dose group over 72 weeks, but it still lags behind the significant weight loss achieved by injectable semaglutide [6]. Group 4: Dosage Strategy - Semaglutide employs different dosage strategies for diabetes and weight loss, with lower doses for diabetes and higher doses for weight loss, which affects the efficacy outcomes [7]. - Orforglipron's current research indicates a closer dosage strategy for diabetes and weight loss, leading to stronger performance in diabetes but not yet achieving the same level of advantage in obesity [7]. Group 5: Future Implications - The results from ACHIEVE-3 suggest that oral GLP-1s can compete effectively in the diabetes market, appealing to patients who prefer not to inject [7]. - The competition in the obesity market will depend on the ability to balance weight loss magnitude, tolerability, and long-term maintenance, indicating that a single trial victory does not determine overall success [7].